Real-world sequential treatment patterns and outcomes in the new era of immunotherapy for advanced gastric cancer in Japan
After first-line nivolumab was introduced for AGC in Japan, treatment patterns remained consistent with Japanese Gastric Cancer Association guidelines. Optimizing sequential therapy, including nivolumab at first-line and ramucirumab combination at second-line, may improve outcomes.
Authors
- Yoshinori Tanizawa (ORCID: https://orcid.org/0000-0002-5014-2483)
- T. Shimizu
- Hisato Kawakami
Institutions
- Tohoku University (JP)
- Eli Lilly (Japan) (JP)
Publication Details
- Journal
- Future Oncology
- Published
- 2026-03-24
- DOI
- https://doi.org/10.1080/14796694.2026.2642222
- Primary Topic
- Gastric Cancer Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00